To determine the clinical effectiveness and safety of dabigatran or rivaroxaban compared to low-molecular-weight heparins (LMWH), unfractionated heparin, warfarin, or fondaparinux for thromboprophylaxis after elective total hip replacement, elective total knee replacement, or hip fracture surgery